Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: In the third quarter, revenue grew 27% to $11.7 million and the net loss reached $22.7 million, or $0.30 per share. The loss was partly because of litigation expenses, of which $7 million was a non-cash charge.
Now what: Sequenom, a genomic sciences company, said capital reserves would be enough to fund operations through mid-2011, but I'm wondering how long it can make it after that. Wide losses are predicted through 2011, forcing me to stay away from this speculative company. I'll sit out until I see a solid profit and a quarter when the company doesn't miss expectations.
Interested in more info on Sequenom? Add it to your watchlist by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his Motley Fool CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.